Monte Rosa Therapeutics Inc

NASDAQ GLUE

Data sourced from

and

Download Data

Monte Rosa Therapeutics Inc Sales to Operating Cash Flow Ratio 1 year YoY Change (%) for the quarter ending September 19, 2024

Monte Rosa Therapeutics Inc Sales to Operating Cash Flow Ratio 1 year YoY Change (%) is NA for the quarter ending September 19, 2024. Sales to operating cash flow ratio measures the revenue generated by a company relative to its operating cash flow. It is calculated by dividing the revenue by the operating cash flow. This ratio provides insights into the efficiency of revenue generation compared to the company's operating cash flow. A higher sales to operating cash flow ratio suggests better revenue generation efficiency. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Monte Rosa Therapeutics Inc Sales to Operating Cash Flow Ratio for the quarter ending March 31, 2023 was -0.00, a 0.00% change year over year.
Monte Rosa Therapeutics Inc Sales to Operating Cash Flow Ratio for the quarter ending March 31, 2022 was -0.00, a 0.00% change year over year.
Monte Rosa Therapeutics Inc Sales to Operating Cash Flow Ratio for the quarter ending March 31, 2021 was -0.00, a 0.00% change year over year.
Monte Rosa Therapeutics Inc Sales to Operating Cash Flow Ratio for the quarter ending March 31, 2020 was -0.00.

NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO	Dr. Markus Warmuth M.D.
IPO Date	June 24, 2021
Location	United States
Headquarters	645 Summer Street, Boston, MA, United States, 02210
Employees	130
Sector	Healthcare
Industry	Biotechnology

Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Key trends